New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 1, 2022, the FDA announced that it has withdrawn its approval for Ukoniq (umbralisib) due to safety concerns.
Download PDF
Return to publications
